Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376916
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-04-15
Brief Title:
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Sponsor:
Aurora Health Care
Organization:
Aurora Health Care
Study Overview
Official Title:
Atrial Tachycardia Reduction With Intravenous Use of Magnesium ATRIUM Study Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATRIUM
Brief Summary:
The purpose of this prospective randomized double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR
Detailed Description:
Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications such as its use in atrial fibrillation or atrial flutter with rapid ventricular response AFF RVR Though its benefit in the treatment of AFF RVR has been well documented a consensus on the optimal dosing of magnesium has yet to be achieved Only one randomized controlled double-blinded study has investigated the optimal dosing of magnesium
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None